This contrasts with a prior clinical study where treatment with sorafenib, a multikinase inhibitor targeting mainly VEGF receptors, in RCC led to decreased 111In-bevacizumab uptake and did not correlate with VEGF levels [18]. Here, VEGFA is linked to renal cell carcinoma.